The Lancet Haematology Publishes Results From Oncopeptides’ Multicenter, International Phase 1/2 Study (O-12-M1)
- Tuesday, March 24, 2020, 7:17
- PR Newswire
- Add a comment
STOCKHOLM, March 24, 2020 /PRNewswire/ — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today the publication of results from its O-12-M1 study, melflufen plus dexamethasone in relapsed/refractory multiple myeloma (RRMM), a multicenter, international, open-label, phase 1/2 study in…
About the Author
admin has written 21840 stories on this site.